NF-kappa-B decoy oligonucleotide - AnGes MG

Drug Profile

NF-kappa-B decoy oligonucleotide - AnGes MG

Alternative Names: AMG0101; AMG0102; AMG0103; AMS-001; MP 40; MP 41; MP 42; NDON; NF-kappa-B decoy oligo; NF-kappaB decoy; NF-kB decoy oligo; S-414114; SI-3104

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnGes MG; Osaka University
  • Developer Aichi Gakuin University; AnGes MG; Hosokawa Micron Corporation; Medikit; Morishita Jintan; Nippon Zoki; Osaka University
  • Class Analgesics; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oligonucleotides; Skin disorder therapies
  • Mechanism of Action Genetic transcription modulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase I Back pain
  • Clinical Phase Unknown Vascular restenosis
  • Preclinical Inflammatory bowel diseases; Intervertebral disc degeneration; Musculoskeletal disorders; Pain; Respiratory tract disorders
  • Discontinued Periodontal disorders; Psoriasis; Spondylosis

Most Recent Events

  • 01 Feb 2018 Phase-Ib clinical trials in Back pain in USA (Intra-articular) (NCT03263611)
  • 07 Sep 2017 NF-kappa-B decoy oligonucleotide is still at phase III development stage for moderate to severe facial Atopic dermatitis in Japan (Topical) (AnGes MG pipeline, July 2017)
  • 25 Apr 2017 The US FDA clears the Investigational New Drug application for discogenic lower back pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top